GLP-1 family
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a phase 1b trial
Enebo LB, Berthelsen KK, Kankam M, et al. · Lancet · 2021
PMID: 33894838 · DOI: 10.1016/S0140-6736(21)00845-X
Summary
Randomized, controlled phase 1b trial characterizing safety, PK and PD of concomitant subcutaneous cagrilintide (amylin analogue) escalated 0.16 to 4.5 mg with semaglutide 2.4 mg once weekly over 20 weeks. Endpoints: tolerability, exposure, body-weight change.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →AMY-ALong-acting amylin analog class agonist studied alongside incretin-receptor agonists in metabolic-pathway research.
More GLP-1 family citations
- Once-Weekly Semaglutide in Adults with Overweight or ObesityN Engl J Med · 2021
- Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)Lancet · 2021
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3)JAMA · 2021